Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of DeathEdward Abraham, William L. Macias, Pierre‐François Laterre et al.|New England Journal of Medicine|2005Cited by 890
Confirmatory interleukin-1 receptor antagonist trial in severe sepsisSteven M. Opal, Michael G. Seneff, John F. LaBrecque et al.|Critical Care Medicine|1997Cited by 863
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Evaluate the Safety and Efficacy of Recombinant Human Soluble Thrombomodulin, ART-123, in Patients With Sepsis and Suspected Disseminated Intravascular Coagulation*Jean‐Louis Vincent, Inder Kaul, M Ramesh et al.|Critical Care Medicine|2013Cited by 322
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisE. Wesley Ely, Gordon R. Bernard, Pierre‐François Laterre et al.|Critical Care Medicine|2003Cited by 283
Systemic Host Responses in Severe Sepsis Analyzed by Causative Microorganism and Treatment Effects of Drotrecogin Alfa (Activated)Steven M. Opal, Gordon R. Bernard, Gary Garber et al.|Clinical Infectious Diseases|2003Cited by 192